{"id":"sal-0951-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"5-10%","effect":"Increased urination"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SAL-0951 tablets work by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in patients with type 2 diabetes. By reducing glucose reabsorption, SAL-0951 tablets also have a mild diuretic effect, which can help to reduce blood pressure.","oneSentence":"SAL-0951 tablets are a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:13.340Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT06737081","phase":"PHASE2","title":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","status":"RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2024-09-14","conditions":"Anemia","enrollment":60},{"nctId":"NCT06720025","phase":"PHASE3","title":"Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2023-09-19","conditions":"Anemia","enrollment":100},{"nctId":"NCT06720233","phase":"PHASE3","title":"Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2002-02-22","conditions":"Anemia","enrollment":37},{"nctId":"NCT06016036","phase":"PHASE3","title":"SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2020-12-08","conditions":"Renal Anemia in Non-dialysis Chronic Kidney Disease","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SAL-0951 group"],"phase":"phase_3","status":"active","brandName":"SAL-0951 tablets","genericName":"SAL-0951 tablets","companyName":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","companyId":"shenzhen-salubris-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SAL-0951 tablets are being studied in clinical trials for the treatment of Anemia and Renal Anemia in Non-dialysis Chronic Kidney Disease. The exact mechanism of SAL-0951 tablets is not specified in the provided facts, but it is being investigated in a Phase II clinical study.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}